

Product Information

**VRK2, active, GST-tagged, human
PRECISIO® Kinase
recombinant, expressed in Sf9 cells**

Catalog Number **SRP5289**
Storage Temperature $-70\text{ }^{\circ}\text{C}$

Product Description

VRK2 (also known as vaccinia related kinase 2) is a member of the vaccinia-related kinase (VRK) family of serine/threonine protein kinases. VRK2 is widely expressed in human tissues and highly expressed in actively dividing cells, such as those in testis, leukocytes, fetal liver, and carcinomas.¹ VRK2 can be used to phosphorylate casein and itself undergo autophosphorylation. VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and this interaction is involved in protecting cells from apoptosis.²

Recombinant human VRK2 (1-375) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST-tag. The VRK2 gene accession number is NM_006296. It is supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, and 25% glycerol.

Molecular mass: ~66 kDa

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

The product ships on dry ice and storage at $-70\text{ }^{\circ}\text{C}$ is recommended. After opening, aliquot into smaller quantities and store at $-70\text{ }^{\circ}\text{C}$. Avoid repeated handling and multiple freeze/thaw cycles.

Figure 1.
SDS-PAGE Gel of Typical Lot:
 $\geq 70\%$ (SDS-PAGE, densitometry)





Figure 2.
Specific Activity of Typical Lot:
9.6–14.4 nmole/min/mg



Procedure

Preparation Instructions

Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM glycerol 2-phosphate, 20 mM MgCl_2 , 12.5 mM MnCl_2 , 5 mM EGTA, and 2 mM EDTA. Just prior to use, add DTT to a final concentration of 0.25 mM.

Kinase Dilution Buffer – Dilute the Kinase Assay Buffer 5-fold with a 50 ng/ μL BSA solution.

Kinase Solution – Dilute the active VRK2 (0.1 µg/µL) with Kinase Dilution Buffer to the desired concentration.

Note: The specific activity plot may be used as a guideline (see Figure 2). It is recommended the researcher perform a serial dilution of active VRK2 kinase for optimal results.

10 mM ATP Stock Solution – Dissolve 55 mg of ATP in 10 mL of Kinase Assay Buffer. Store in 200 µL aliquots at –20 °C.

γ-³³P-ATP Assay Cocktail (250 µM) – Combine 5.75 mL of Kinase Assay Buffer, 150 µL of 10 mM ATP Stock Solution, 100 µL of γ-³³P-ATP (1 mCi/100 µL). Store in 1 mL aliquots at –20 °C.

Substrate Solution – Dissolve the protein substrate in distilled water at a final concentration of 1 mg/mL.

1% phosphoric acid solution – Dilute 10 mL of concentrated phosphoric acid to a final volume of 1 L with water.

Kinase Assay

This assay involves the use of the ³³P radioisotope. All institutional guidelines regarding the use of radioisotopes should be followed.

1. Thaw the active VRK2, Kinase Assay Buffer, Substrate Solution, and Kinase Dilution Buffer on ice. The γ-³³P-ATP Assay Cocktail may be thawed at room temperature.
2. In a pre-cooled microcentrifuge tube, add the following solutions to a volume of 20 µL:
 - 10 µL of Kinase Solution
 - 5 µL of Substrate Solution
 - 5 µL of cold water (4 °C)
3. Set up a blank control as outlined in step 2, substituting 5 µL of cold water (4 °C) for the Substrate Solution.
4. Initiate each reaction with the addition of 5 µL of the γ-³³P-ATP Assay Cocktail, bringing the final reaction volume to 25 µL. Incubate the mixture in a water bath at 30 °C for 15 minutes.
5. After the 15 minute incubation, stop the reaction by spotting 20 µL of the reaction mixture onto an individually pre-cut strip of phosphocellulose P81 paper.

6. Air dry the pre-cut P81 strip and sequentially wash in the 1% phosphoric acid solution with constant gentle stirring. It is recommended the strips be washed a total of 3 times of ~10 minutes each.
7. Set up a radioactive control to measure the total γ-³³P-ATP counts introduced into the reaction. Spot 5 µL of the γ-³³P-ATP Assay Cocktail on a pre-cut P81 strip. Dry the sample for 2 minutes and read the counts. Do not wash this sample.
8. Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
9. Determine the corrected cpm by subtracting the blank control value (see step 3) from each sample and calculate the kinase specific activity

Calculations:

1. Specific Radioactivity (SR) of ATP (cpm/nmole)

$$SR = \frac{\text{cpm of 5 } \mu\text{L of } \gamma\text{-}^{33}\text{P-ATP Assay Cocktail}}{\text{nmole of ATP}}$$

cpm – value from control (step 7)
nmole – 1.25 nmole (5 µL of 250 µM ATP Assay Cocktail)

2. Specific Kinase Activity (SA) (nmole/min/mg)

$$\text{nmole/min/mg} = \frac{\Delta\text{cpm} \times (25/20)}{SR \times E \times T}$$

SR = specific radioactivity of the ATP (cpm/nmole ATP)

Δcpm = cpm of the sample – cpm of the blank (step 3)

25 = total reaction volume

20 = spot volume

T = reaction time (minutes)

E = amount of enzyme (mg)

References

1. Nezu, J. et al., Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. *Genomics*, **45**, 327-331 (1997).
2. Li, L.-Y. et al., The cellular protein PRA1 modulates the anti-apoptotic activity of Epstein-Barr virus BHRF1, a homologue of Bcl-2, through direct interaction. *J. Biol. Chem.*, **276**, 27354–27362 (2001).

PRECISIO is a registered trademark of Sigma-Aldrich Co. LLC.

RC,MAM 12/12-1